IRIS - Res&Arch Institutional Research Information System - Research & Archive

Roila, Fausto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.726
EU - Europa 1.381
AS - Asia 767
SA - Sud America 135
AF - Africa 9
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 4.021
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.700
SG - Singapore 478
IE - Irlanda 468
IT - Italia 309
RU - Federazione Russa 213
HK - Hong Kong 188
BR - Brasile 129
FR - Francia 97
DE - Germania 68
UA - Ucraina 66
CN - Cina 59
SE - Svezia 52
FI - Finlandia 41
AT - Austria 20
BE - Belgio 15
CA - Canada 14
GB - Regno Unito 12
NL - Olanda 11
TR - Turchia 9
MX - Messico 6
AR - Argentina 4
IQ - Iraq 4
KR - Corea 4
PK - Pakistan 4
BG - Bulgaria 3
CH - Svizzera 3
PH - Filippine 3
GE - Georgia 2
GH - Ghana 2
HN - Honduras 2
IN - India 2
JM - Giamaica 2
JP - Giappone 2
MA - Marocco 2
MY - Malesia 2
VN - Vietnam 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
CL - Cile 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EC - Ecuador 1
EG - Egitto 1
EU - Europa 1
GR - Grecia 1
IS - Islanda 1
JO - Giordania 1
KZ - Kazakistan 1
LT - Lituania 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PA - Panama 1
QA - Qatar 1
TN - Tunisia 1
TW - Taiwan 1
UZ - Uzbekistan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.021
Salva come PNG Salva come JPEG
Città #
Dublin 468
Chandler 347
Singapore 303
Hong Kong 188
Boardman 161
Santa Clara 139
Altamura 135
Princeton 130
Medford 127
Lawrence 124
Moscow 116
Perugia 55
Los Angeles 40
Jacksonville 35
San Mateo 33
The Dalles 27
Helsinki 26
Redmond 26
Andover 25
Ann Arbor 25
San Paolo di Civitate 20
Nuremberg 17
Wilmington 16
Brussels 15
Rome 14
Ashburn 11
Napoli 11
Falkenstein 10
Houston 10
São Paulo 10
New York 9
Toronto 9
Boydton 8
Munich 8
Shanghai 8
Bologna 7
Huskvarna 7
Norwalk 7
Dallas 6
Des Moines 6
Milan 6
Istanbul 5
Vienna 5
Amsterdam 4
Beijing 4
Belo Horizonte 4
Chicago 4
Guangzhou 4
Lappeenranta 4
Paris 4
Seoul 4
Woodbridge 4
Ancona 3
Auburn Hills 3
Brasília 3
Curitiba 3
Hanover 3
Jequié 3
Saint Petersburg 3
São José dos Campos 3
Vicenza 3
Wuhan 3
Accra 2
Akishima 2
Baghdad 2
Campinas 2
Canoas 2
Cape Town 2
Caratinga 2
Council Bluffs 2
El Progreso 2
Falls Church 2
Foligno 2
Forlì 2
Frankfurt am Main 2
Goiânia 2
Hanoi 2
Jandira 2
Kingston 2
Lahore 2
Loughborough 2
Mexico City 2
Montréal 2
Naples 2
Ostra Vetere 2
Padova 2
Porcia 2
Recife 2
Reggio Emilia 2
Sofia 2
Terni 2
Turin 2
Abelardo Luz 1
Almaty 1
Alushta 1
Amelia 1
Amman 1
Angeles 1
Annaba 1
Aprilia 1
Totale 2.889
Salva come PNG Salva come JPEG
Nome #
Primitive thyroid lymphomas 98
Supportive care in cancer—a MASCC perspective 92
Invasive ductal carcinoma arising in ectopic breast tissue of the axilla. Case report and review of the literature 83
Linee guida per la gestione dei pazienti affetti da melanoma cutaneo 72
High incidence of brain metastases in HER2-overexpressing metastatic breast cancer (MBC) patients (PTS) responsive to weekly paclitaxel (P) and trastuzumab (T) treatment. 5 National Congress of Medical Oncology, Rome, 21-24 October 2003. 71
Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool 70
Surgical treatment of primitive thyroid lymphoma 67
NICSO: Network Italiano Cure di Supporto in Oncologia – Italian Network for Supportive Care in Oncology 58
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy 55
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 >= 50% who progress on first-line immunotherapy: real-world data from a European cohort 54
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients 54
XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. 51
Incidence, characteristics and treatment of fatigue in oncological cancer patients (PTS) in Italy: A cross-sectional study. 51
Use of Electronic Administrative Databases to Measure Quality Indicators of Breast Cancer Care: Experience of Five Regional Oncology Networks in Italy 51
Ginger in the management of chemotherapy induced nausea and vomiting (CINV), in patients receiving high dose cisplatin: a multicenter, randomized, double-blind, placebo-controlled study 50
Raccomandazioni cliniche per il melanoma cutaneo 50
Renal malignant solitary fibrous tumor with single lymph node involvement: report of unusual metastasis and review of the literature. 50
Higher tlr7 gene expression predicts poor clinical outcome in advanced nsclc patients treated with immunotherapy 50
Sensitivity to immune checkpoint blockade in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations 48
Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis 46
Optimal Management of Fatigue 45
Prevention and treatment of pandemic influenza in cancer patients. 44
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients 44
Real-World Results in Non-Squamous Non-Small Cell Lung Cancer Patients: Italian Nivolumab Expanded Access Program 44
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab 44
Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines 44
Efficacy of Pembrolizumab Monotherapy in Patients with or without Brain Metastases from Advanced Non-Small Cell Lung Cancer with a PD-L1 Expression ≥50% 43
2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy 43
Italian nivolumab expanded access programme: real-world results in non-squamous non-small cell lung cancer patients 41
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) 41
Aprepitant versus metoclopramide, both combined with dexamethasone, for preventing cisplatin-induced delayed emesis: A randomized, double-blind study 41
Targeted therapy for advanced cutaneous melanoma 40
Juvenile papillomatosis of the breast in young male: a case report 40
Aprepitant Versus Dexamethasone for Preventing Chemotherapy-Induced Delayed Emesis in Patients With Breast Cancer: A Randomized Double-Blind Study 40
Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment 40
Aprepitant (AP) versus dexamethasone (D) for preventing delayed emesis induced by anthracyclines plus cyclophosphamide (A plus C) chemotherapy (CT) in breast cancer patients (pts): A double-blind, multicenter, randomized study 39
Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: An effective but still broken option 38
Detection of egfr mutations in plasma cell-free tumor dna of tki-treated advanced-nsclc patients by three methodologies: Scorpion-arms, pnaclamp, and digital pcr 38
Prevalence and spectrum of brca germline variants in central Italian high risk or familial breast/ovarian cancer patients: A monocentric study 38
Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009 38
Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time? 37
Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma 37
Chemotherapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxis 36
2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting 36
Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis 35
Efficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis 35
Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature 35
New antiemetic drugs 34
2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy 31
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: A randomized, double-blind study 31
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial 31
Incidence, characteristics and treatment of fatigue in oncological cancer patients (pts) in italy: a cross-section study 30
Aprepitant Versus Dexamethasone for Delayed Emesis: What Is the Role of the 5-Hydroxytryptamine Type 3 Receptor Antagonist Palonosetron? Reply 30
Diagnosis and therapeutic management of parathyroid cancer, starting from the description of a clinical case 29
Chemotherapy-induced nausea and vomiting 28
Anticipatory Nausea, Risk Factors, and Its Impact on Chemotherapy-Induced Nausea and Vomiting: Results From the Pan European Emesis Registry Study 28
Efficacy and safety data from patients with advanced non-squamous NSCLC and brain metastases from the nivolumab expanded access programme (EAP) in Italy 28
Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy 27
The impact of chemotherapy-induced nausea and vomiting on health-related quality of life 27
Conflict of interest among Italian medical oncologists: A national survey 27
Acute emesis: moderately emetogenic chemotherapy 27
Chemotherapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxis 27
Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy 26
Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO) 26
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 26
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference 26
Management of venous thromboembolism in cancer patients: ESMO Clinical Recommendations 25
Management of oral and gastrointestinal mucositis: ESMO Clinical Recommendations 25
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines 25
Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol-EASE 24
Management of venous thromboembolism in cancer patients: ESMO Clinical Recommendations 24
Optimizing the risk stratification of astrocytic tumors by applying the cIMPACT-NOW Update 3 signature: real-word single center experience 23
Daily challenges in oncology practice. What do we need to know about antiemetics? 23
Colorectal cancer and cardiovascular diseases: Are we closing the gap between knowledge and action? 23
Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review 23
Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference 23
Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer 22
DOACs in patients with brain cancers: promising but still a long way to go 22
Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines 22
A new payment-by-results method for determining the fair price of new oncological drugs 22
The cost of chemotherapy-induced nausea and vomiting in Italy 22
PAINTER: Evaluation of eribulin tolerability and correlation between a set of polymorphisms and neuropathy in patients with metastatic breast cancer 22
Hepatitis B in immunosuppressed cancer patients:pathogenesis, incidence and prophylaxis 21
Erythropoiesis-stimulating agents in cancer patients: ESMO Recommendations for use 21
Prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Guideline update and results of the Perugia consensus conference 21
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 21
A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients 21
Proton Pump Inhibitors in cancer patients: How useful they are? A review of the most common indications for their use 21
Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines 20
Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines 20
Searching for evidence to support the use of ginger in the prevention of chemotherapy-induced nausea and vomiting 20
State of the art of antiemetic therapy 20
Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders 20
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer 20
Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting (Reprinted) 20
BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors 19
New anti-emetic treatments 19
MASCC/ESMO Antiemetic Guidelines: Introduction to the 2016 guideline update 19
Malignant glioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up 19
Tackling Off-Label Use of Anticancer Drugs 19
Totale 3.567
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.243
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.243
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20207 0 0 0 0 0 0 0 0 0 0 1 6
2020/2021138 1 8 7 14 36 8 10 1 23 10 16 4
2021/2022522 3 29 6 11 7 2 4 160 8 24 21 247
2022/20231.478 150 371 32 57 105 78 0 53 557 9 45 21
2023/2024585 28 47 25 14 10 2 128 13 39 40 107 132
2024/20251.352 9 165 27 63 198 74 50 147 470 116 33 0
Totale 4.189